ДАС Аша (US),ГИХАРРО Ана Мария Абахо (CH),АБРИ Лорен (CH),ГАРСИЯ Хосеп (CH),ХИЛТОН Магали (CH),КЕРЛОЕГУЕН Янник (CH),МУР Никола (CH)
申请号：
RU2015104001
公开号：
RU2015104001A
申请日:
2013.08.06
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A method of treating a patient diagnosed with glioblastoma, comprising administering to the patient a therapy comprising an effective amount of an anti-VEGF antibody, an effective amount of a chemotherapeutic agent and an effective amount of radiation therapy, where the treatment increases the median survival without progression of the patient compared to a patient with glioblastoma receiving a chemotherapeutic agent without anti-VEGF antibody. 2. The method according to claim 1, where the patient has an indicator of the general condition of WHO≤2.3. The method of claim 1, wherein the chemotherapeutic agent is temozolomide. The method of claim 3, wherein temozolomide is administered at a dose of 150 mg / m. The method of claim 3, wherein temozolomide is administered at a dose of 200 mg / m. The method of claim 1, wherein the anti-VEGF antibody binds to the A4.6.1.7 epitope. The method of claim 1, wherein the anti-VEGF antibody is bevacizumab. The method of claim 1, wherein the anti-VEGF antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), where VH has the amino acid sequence of SEQ ID NO: 2 and VL has the amino acid sequence of SEQ ID NO: 1.9. The method of claim 1, wherein the effective amount of the anti-VEGF antibody is 10 mg / kg intravenously every two weeks. The method of claim 1, wherein the effective amount of said anti-VEGF antibody is 15 mg / kg intravenously every three weeks. The method of claim 1, wherein the effective amount of said anti-VEGF antibody is first administered intravenously for 90 minutes, then the infusion is carried out for 60 minutes, and then for 30 minutes. The method of claim 1, wherein the anti-VEGF antibody is administered first to said patient in a first cycle. The method of claim 9, wherein subsequent administration of the anti-VEGF antibody is performed either before or after administration of the chemotherapeutic agent. The method of claim 1, wherein the anti-VEGF antibody is administ
